Profile data is unavailable for this security.
About the company
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
- Revenue in USD (TTM)360.35m
- Net income in USD-149.57m
- Incorporated1998
- Employees907.00
- LocationGlaukos Corp1 GLAUKOS WAYALISO VIEJO 92656United StatesUSA
- Phone+1 (949) 367-9600
- Fax+1 (949) 367-9984
- Websitehttps://www.glaukos.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integer Holdings Corp | 1.68bn | 114.44m | 4.56bn | 10.50k | 41.89 | 2.81 | 20.60 | 2.71 | 3.24 | 3.22 | 47.87 | 48.33 | 0.5594 | 4.93 | 5.14 | 160,023.80 | 3.81 | 3.28 | 4.10 | 3.53 | 27.06 | 26.94 | 6.81 | 6.40 | 2.09 | 4.11 | 0.4028 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
| Procept Biorobotics Corp | 199.84m | -100.06m | 5.11bn | 626.00 | -- | 20.42 | -- | 25.55 | -1.95 | -1.95 | 3.89 | 4.63 | 0.5026 | 1.83 | 3.86 | 319,238.00 | -25.16 | -- | -28.58 | -- | 57.39 | -- | -50.07 | -- | 5.07 | -- | 0.1758 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Inspire Medical Systems Inc | 755.59m | 33.05m | 5.58bn | 1.01k | 171.11 | 8.01 | 146.81 | 7.38 | 1.09 | 1.09 | 25.15 | 23.25 | 1.05 | 2.46 | 9.37 | 747,372.90 | 4.60 | -11.27 | 5.12 | -12.60 | 84.77 | 84.47 | 4.37 | -13.57 | 6.94 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Stevanato Group SpA | 1.15bn | 120.12m | 5.94bn | 5.64k | 43.86 | 3.87 | 29.38 | 5.19 | 0.4473 | 0.4473 | 4.26 | 5.07 | 0.5284 | 2.75 | 2.66 | 203,340.60 | 5.54 | -- | 7.39 | -- | 29.20 | -- | 10.48 | -- | 1.21 | 48.53 | 0.2148 | -- | 10.34 | -- | 1.95 | -- | -- | -- |
| Lantheus Holdings Inc | 1.50bn | 427.61m | 6.07bn | 834.00 | 14.51 | 5.15 | 12.39 | 4.06 | 6.02 | 6.02 | 21.09 | 16.97 | 0.8383 | 8.28 | 5.09 | 1,794,723.00 | 23.95 | 6.69 | 32.76 | 7.73 | 64.78 | 57.56 | 28.57 | 9.02 | 1.56 | -- | 0.324 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Merit Medical Systems Inc | 1.33bn | 120.04m | 6.12bn | 6.95k | 51.45 | 4.62 | 28.11 | 4.62 | 2.04 | 2.04 | 22.55 | 22.71 | 0.6334 | 2.29 | 7.41 | 190,772.80 | 5.73 | 2.45 | 6.32 | 2.77 | 46.83 | 44.50 | 9.05 | 3.91 | 3.82 | 31.88 | 0.3619 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Glaukos Corp | 360.35m | -149.57m | 7.77bn | 907.00 | -- | 11.61 | -- | 21.55 | -2.96 | -2.96 | 7.06 | 12.13 | 0.3843 | 1.69 | 7.53 | 397,295.50 | -15.95 | -8.73 | -17.23 | -9.35 | 76.61 | 74.77 | -41.51 | -28.69 | 4.71 | -311.24 | 0.1591 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Repligen Corp | 622.64m | -17.13m | 7.94bn | 1.78k | -- | 3.94 | 154.72 | 12.75 | -0.3079 | -0.3079 | 11.09 | 36.00 | 0.233 | 1.57 | 5.29 | 349,206.40 | -0.6411 | 4.38 | -0.7032 | 5.03 | 50.37 | 55.43 | -2.75 | 15.91 | 8.76 | -- | 0.2055 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Bruker Corp | 3.24bn | 304.90m | 8.52bn | 9.71k | 27.11 | 4.72 | 18.05 | 2.63 | 2.07 | 2.07 | 21.89 | 11.92 | 0.6527 | 1.51 | 5.73 | 333,913.70 | 6.12 | 8.38 | 8.14 | 11.40 | 49.31 | 49.85 | 9.38 | 11.39 | 0.7085 | 26.83 | 0.5549 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
| Teleflex Inc | 3.03bn | 238.01m | 8.85bn | 14.50k | 37.80 | 1.98 | 17.53 | 2.93 | 5.04 | 5.03 | 64.01 | 96.50 | 0.404 | 2.11 | 6.76 | 208,677.50 | 3.18 | 5.86 | 3.46 | 6.42 | 55.99 | 54.43 | 7.87 | 14.62 | 1.39 | 6.61 | 0.2818 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
| Masimo Corp | 2.04bn | 78.60m | 9.05bn | 3.80k | 116.32 | 6.18 | 52.25 | 4.43 | 1.45 | 1.45 | 37.72 | 27.35 | 0.6715 | 1.77 | 5.52 | 537,526.30 | 2.58 | 8.65 | 3.23 | 10.31 | 50.05 | 57.30 | 3.85 | 12.03 | 1.11 | 2.84 | 0.3456 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
| Bio Rad Laboratories Inc | 2.58bn | -778.69m | 9.16bn | 8.03k | -- | 1.22 | -- | 3.55 | -27.32 | -27.32 | 90.77 | 267.46 | 0.2294 | 1.49 | 5.61 | 321,321.20 | -6.92 | 9.08 | -7.26 | 9.60 | 54.43 | 55.55 | -30.18 | 41.97 | 4.52 | 0.2612 | 0.1383 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Henry Schein, Inc. | 12.50bn | 314.00m | 9.20bn | 25.00k | 30.21 | 2.64 | 15.54 | 0.7359 | 2.44 | 2.44 | 96.89 | 27.99 | 1.22 | 4.77 | 7.73 | 499,960.00 | 2.97 | 6.09 | 4.86 | 10.44 | 31.59 | 30.04 | 2.42 | 4.40 | 0.817 | 6.23 | 0.348 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Penumbra Inc | 1.16bn | 34.55m | 9.23bn | 4.20k | 279.56 | 8.35 | 151.56 | 7.93 | 0.8602 | 0.8602 | 29.71 | 28.78 | 0.7897 | 1.04 | 6.08 | 277,089.50 | 2.34 | 2.32 | 2.61 | 2.61 | 65.70 | 63.90 | 2.97 | 3.17 | 3.25 | -- | 0.0218 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
Data as of Nov 23 2024. Currency figures normalised to Glaukos Corp's reporting currency: US Dollar USD
54.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.75m | 14.10% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.72m | 10.41% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.57m | 10.13% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.11m | 3.85% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.95m | 3.56% |
| Brown Capital Management LLCas of 30 Sep 2024 | 1.63m | 2.98% |
| Lord, Abbett & Co. LLCas of 30 Sep 2024 | 1.53m | 2.78% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 1.30m | 2.37% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 1.25m | 2.27% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.17m | 2.13% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
